Brief: OSE Immunotherapeutics Launches Phase 2 Trial Of Tedopi With Opdivo In Lung Cancer
27/05/2021 17:13
May 27 (Reuters) - Ose Immunotherapeutics SA OSE.PA :
* OSE IMMUNOTHERAPEUTICS AND THE FORT FOUNDATION ANNOUNCE
INITIATION OF A PHASE 2 CLINICAL TRIAL EVALUATING TEDOPI IN
COMBINATION WITH OPDIVO (NIVOLUMAB) IN NON-SMALL CELL LUNG
CANCER
Source text for Eikon: ID:nGNXrJMKx
Further company coverage: OSE.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Ose Immunotherapeutics SA
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Brief: OSE Immunotherapeutics SA Appoints Thomas Gidoin As Deputy CEO
Brief: Ose Immunotherapeutics Will Pause Development Of OSE‑230
Brief: OSE Immunotherapeutics Gets Second Positive IDMC Nod For Phase 3 Lung Cancer Trial
Brief: OSE Immunotherapeutics Announces Appointment Of Marc Le Bozec As Interim CEO